Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02758132 · ClinicalTrials.gov registry record · Phase 2
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
A Phase 2 study, sponsored by University of Hawaii.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02758132 is a Phase 2 study that was terminated before completion, run by University of Hawaii. The registered enrollment target is 1 participants.
The verdict
NCT02758132, a Phase 2 study, was terminated before completion, sponsored by University of Hawaii.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone
- BIOLOGICAL Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2016-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02758132
The ClinicalTrials.gov registry entry for NCT02758132 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT02758132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02758132 about?
NCT02758132 is a clinical study titled "Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases". This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.
What is the current status of trial NCT02758132?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-03-01. Estimated completion is 2016-09-06.
What interventions are being tested in trial NCT02758132?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), Denosumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02758132?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.